Last reviewed · How we verify
Standard bismuth quadruple
Standard bismuth quadruple therapy combines bismuth salts with antibiotics and acid suppression to eradicate Helicobacter pylori infection through multiple mechanisms including direct bacterial toxicity and reduced antibiotic resistance.
Standard bismuth quadruple therapy combines bismuth salts with antibiotics and acid suppression to eradicate Helicobacter pylori infection through multiple mechanisms including direct bacterial toxicity and reduced antibiotic resistance. Used for Helicobacter pylori infection eradication in peptic ulcer disease, H. pylori-associated chronic gastritis.
At a glance
| Generic name | Standard bismuth quadruple |
|---|---|
| Sponsor | Xijing Hospital of Digestive Diseases |
| Drug class | Antibiotic combination therapy / Bismuth-based anti-ulcer agent |
| Target | Helicobacter pylori (bacterial pathogen) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Bismuth quadruple therapy typically consists of bismuth subsalicylate or bismuth subcitrate, two antibiotics (commonly metronidazole and tetracycline), and a proton pump inhibitor or H2-receptor antagonist. Bismuth acts as a bactericidal agent against H. pylori while the antibiotics provide synergistic antimicrobial activity, and acid suppression creates an optimal environment for bacterial eradication and mucosal healing.
Approved indications
- Helicobacter pylori infection eradication in peptic ulcer disease
- H. pylori-associated chronic gastritis
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Metallic taste
- Black stool discoloration
- Headache
Key clinical trials
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (NA)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy (PHASE4)
- The Efficacy and Safety of Keverprazan for Helicobacter Pylori Eradication (EARLY_PHASE1)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
- Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication (PHASE4)
- H. Pylori Screen-and-treat Study in a Population of Young Adults
- Bismuth Quadruple Therapy Versus Standard Triple Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard bismuth quadruple CI brief — competitive landscape report
- Standard bismuth quadruple updates RSS · CI watch RSS
- Xijing Hospital of Digestive Diseases portfolio CI